TrialJournal for immunotherapy of cancer2022

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma.

Xuefeng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.